P
Pasithea Therapeutics Corp. (KTTA)
NCM – Real Time Price. Currency in USD
0.74
-0.03 (-3.73%)
At close: Mar 27, 2026, 4:00 PM EDT
0.74
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:49 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.74
-0.03 (-3.73%)
At close: Mar 27, 2026, 4:00 PM EDT
0.74
0.00 (0.00%)
After-hours: Mar 27, 2026, 4:49 PM EDT
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Name | Position |
|---|---|
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman |
| Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director |
| Mr. Daniel H. Schneiderman | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-30 | S-8 | ea0274493-s8_pasithea.htm |
| 2026-01-28 | 8-K | ea0274244-8k_pasithea.htm |
| 2026-01-26 | POS AM | ea027402501-posam_pasithea.htm |
| 2025-12-29 | DEF 14A | ea0271056-def14a_pasithea.htm |
| 2025-12-19 | PRE 14A | ea0270324-pre14a_pasithea.htm |
| 2025-12-15 | 8-K | ea0269602-8k_pasithea.htm |
| 2025-12-02 | 8-K | ea0267824-8k_pasithea.htm |
| 2025-11-26 | S-1/A | ea0267537-s1a1_pasithea.htm |
| 2025-11-25 | 8-K | ea0266606-8k_pasithea.htm |
| 2025-11-18 | S-1 | ea0266093-s1_pasithea.htm |